



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/994,068	11/27/2001	Tsutomu Arakawa	06843.0028-02000	8561

22852 7590 09/22/2005

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER  
LLP  
901 NEW YORK AVENUE, NW  
WASHINGTON, DC 20001-4413

EXAMINER
----------

GODDARD, LAURA B

ART UNIT	PAPER NUMBER
----------	--------------

1642

DATE MAILED: 09/22/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER
----------

ART UNIT	PAPER
----------	-------

1

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.8821 (a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reasons(s) set forth on the attached Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer from the date of this letter within which to comply with the sequence rules, 37 CFR 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821 (g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for response beyond the SIX MONTH statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura B. Goddard, Ph.D. whose telephone number is (571) 272-8788. The examiner can normally be reached on 8:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Laura B Goddard, Ph.D.ExaminerArt Unit 1642

**Office Action Summary**

Application No.

09/994,068

Applicant(s)

ARAKAWA ET AL.

Examiner

Laura B. Goddard, Ph.D.

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 17 August 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 19-24, 29, 30, 42 and 43 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 19-24, 29, 30, 42 and 43 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 12/5/03, 6/18/03, 4/1/04
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

### DETAILED ACTION

1. The Election filed August 17, 2005 in response to the Office Action of June 17, 2005 is acknowledged and has been entered. Applicants elected Group II, claims 19, 29, 30, 42, and 43 without traverse. Upon review and reconsideration, claims 20-24 are rejoined. Claims 19-24, 29, 30, 42, and 43 are currently under prosecution.

### *Specification*

2. The disclosure is objected to because it does not comply with the sequence rules:

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.8821 (a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reasons(s) set forth on the attached Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. In particular, no sequence identifier is associated with the sequences disclosed on pages 13-16. Although Examiner has made an effort to identify where in the specification such informalities are found, it appears that the specification is replete with such informalities. Applicant must correct these informalities.

Applicant is given the period of reply for this Action within which to comply with the sequence rules, 37 CFR 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821 (g). Extensions of

Art Unit: 1642

time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for response beyond the SIX MONTH statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claims 24, 42 and 43 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claim is drawn to a method for treating cancer comprising administering an antibody produced from the hybridoma cell line ATCC NO. HB 12078. Since the antibody produced from the hybridoma cell line ATCC NO. HB 12078 is essential to the claimed invention it must be obtainable by a repeatable method set forth in the

Art Unit: 1642

specification or otherwise readily available, the requirements of 35 USC 112 may not be satisfied by a deposit of the antibody or antigen to which it binds. The specification does not disclose a repeatable process to obtain the antibody and it is not apparent if the antibody is readily available to the public. It is noted that Applicant deposited the hybridoma with the ATCC (p. 10, lines 9-13), but there is no indication in the specification as to public availability. When the deposit is made under the Budapest Treaty, then an affidavit or declaration by Applicant, or a statement by an attorney of record over his or her signature and registration number, stating that the specific antibody will be irrevocably and without restriction or condition released to the public upon the issuance of the patent, and that the deposit will be replaced if viable samples cannot be dispensed by the depository is required, would satisfy the deposit requirement made herein.

Amendment of the specification to recite the date of deposit and the complete name and address of the depository is required. As an additional means for completing the record, applicant may submit a copy of the contract with the depository for deposit and maintenance of the deposit.

Finally, Applicant is advised that the address for the ATCC has recently changed, and that the new address should appear in the specification. The new address is:

American Type Culture Collection

10801 University Boulevard

Manassas, VA 20110-2209

4. Claims 19-23, 29, and 30 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. THIS IS A WRITTEN DESCRIPTION REJECTION.

The claims are drawn to a method for treating cancer comprising administering an antibody or fragment thereof, wherein apoptosis is induced in Her2 overexpressing cells. The specification teaches monoclonal antibody mAb74 (produced by the hybridoma ATCC No. HB 12078), wherein treatment of Her2 expressing cells with the antibody resulted in apoptosis (p. 30, lines 3-7). The specification does not disclose any other monoclonal antibodies or fragments thereof inducing apoptosis as broadly encompassed in the claims.

To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, the only factor present in the claim is a recitation of an antibody or fragment thereof. Accordingly, in the absence of sufficient recitation of

Art Unit: 1642

distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

Although drawn to DNA arts, the findings in University of California v. Eli Lilly and Co., 119 F.3d 1559, 43 USPQ2d 1398 (Fed. Cir. 1997) and Enzo Biochem, Inc. V. Gen-Probe Inc. are relevant to the instant claims. The Federal Circuit addressed the application of the written description requirement to DNA-related inventions in University of California v. Eli Lilly and Co., 119 F.3d 1559, 43 USPQ2d 1398 (Fed. Cir. 1997). The court stated that "[a] written description of an invention involving a chemical genus, like a description of a chemical species, 'requires a precise definition, such as by structure, formula, [or] chemical name', of the claimed subject matter sufficient to distinguish it from other materials." *Id.* At 1567, 43 USPQ2d at 1405. The court also stated that:

a generic statement such as "vertebrate insulin cDNA" or "mammalian insulin cDNA" without more, is not an adequate written description of the genus because it does not distinguish the genus from others, except by function. It does not specifically define any of the genes that fall within its definition. It does not define any structural features commonly possessed by members of the genus that distinguish them from others. One skilled in the art therefore cannot, as one can do with a fully described genus, visualize or recognize the identity of the members of the genus. A definition by function, as we have previously indicated, does not suffice to define the genus because it is only an indication of what the gene does, rather than what it is.



Art Unit: 1642

Id. At 1568, 43 USPQ2d at 1406. The court concluded that “naming a type of material generally known to exist, in the absence of knowledge as to what that material consists of, is not a description of that material.” Id.

Finally, the court addressed the manner by which a genus of cDNAs might be described. “A description of a genus of cDNAs may be achieved by means of a recitation of a representative number of cDNAs, defined by nucleotide sequence, falling within the scope of the genus or of a recitation of structural features common to the members of the genus, which features constitute a substantial portion of the genus.” Id.

The Federal Circuit has recently clarified that a DNA molecule can be adequately described without disclosing its complete structure. See Enzo Biochem, Inc. V. Gen-Probe Inc., 296 F.3d 1316, 63 USPQ2d 1609 (Fed. Cir. 2002). The Enzo court adopted the standard that “the written description requirement can be met by show[ing] that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics ....i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics.” Id. At 1324, 63 USPQ2d at 1613 (emphasis omitted, bracketed material in original).

The inventions at issue in Lilly and Enzo were DNA constructs per se, the holdings of those cases are also applicable to claims such as those at issue here. A disclosure that does not adequately describe a product itself logically cannot adequately describe a method of using that product.

Thus, the instant specification may provide an adequate written description of an antibody or fragment thereof, per Lilly by structurally describing representative polypeptides or by describing "structural features common to the members of the genus, which features constitute a substantial portion of the genus." Alternatively, per Enzo, the specification can show that the claimed invention is complete "by disclosure of sufficiently detailed, relevant identifying characteristics, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics."

The specification contemplates the use of the claimed antibody as therapeutic to treat cancer characterized by overexpression of Her2 by inducing apoptosis (p. 11, lines 8-28). In this case, the specification does not directly describe the antibodies useful in the claimed invention in a manner that satisfies either the Lilly or Enzo standards. Although the specification discloses mAb74 (produced by the hybridoma ATCC No. HB 12078), this does not provide a description of the broadly claimed antibodies which induce apoptosis in Her2 overexpressing cells that would satisfy the standard set out in Enzo because the specification provides no functional characteristics coupled to structural features.

Further, the specification also fails to describe the antibodies by the test set out in Lilly because the specification describes only mAb74 (produced by the hybridoma ATCC No. HB 12078) that induces apoptosis in Her2 overexpressing cells. Therefore it necessarily fails to describe a representative number of such species.

Thus, the specification does not provide an adequate written description of an antibody which induces apoptosis in Her2 overexpressing cells. Since the specification fails to adequately describe the antibody it also fails to adequately describe the method for treating cancer.

**Note: If applicant were to overcome the preceding rejection (s) under 35 U.S.C. 112, first paragraph, the following claims would still be rejected under 35 U.S.C. 112, first paragraph, scope of enablement:**

5. Claims 19-24, 29, 30, 42, and 43 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a **method for treating cancer comprising administering mAb74 or fragment thereof to induce apoptosis in Her2 overexpressing cells in cell culture (*in vitro*)**, does not reasonably provide enablement for a **method for treating cancer in a patient comprising administering an antibody or fragment thereof to induce apoptosis in Her2 overexpressing cells *in vivo***. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

The claims are drawn to a method for treating cancer in a patient comprising administering an antibody or fragment thereof to induce apoptosis in Her2 overexpressing cells, this means the claims are drawn to a method for treating cancer *in vivo*. The specification teaches apoptosis induced in cell culture by mAb74 (produced by

Art Unit: 1642

hybridoma ATCC No. HB 12078), wherein the induction of apoptosis was an unexpected result (p. 4, lines 25-28). However, the claims are not enabled because said teachings represent insufficient guidance and objective evidence to predictably enable the use of the claimed invention. Thus, the claims are not enabled for method for treating cancer in a patient *in vivo*. In particular, one cannot extrapolate the teaching of the specification to the scope of the claims because the specification makes it clear that the finding of an antibody that induces apoptosis is an unexpected event. An unexpected event is, by its nature, unpredictable. Although the specification teaches a single antibody with this unexpected property, the specification provides no structure-function relationship, no information as to the epitope bound, thus does not teach how to make the claimed therapeutic. Although the specification teaches that the epitope of mAb74 is distinct from other epitopes (p. 8, line 34), this does not provide sufficient teachings, as the epitope is not identified. Further, although the specification teaches screening of antibodies to determine function, screening assays do not enable the claimed invention because the court found in (*Rochester v. Searle*, 358 F.3d 916, Fed Cir., 2004) that screening assays, are not sufficient to enable an invention because they are merely a wish or plan for obtaining the claimed chemical invention.

Those of skill in the art recognize that *in vitro* assays and or cell-cultured based assays are generally useful to observe basic physiological and cellular phenomenon such as screening the effects of potential drugs. However, clinical correlations are generally lacking. The greatly increased complexity of the *in vivo* environment as compared to the very narrowly defined and controlled conditions of an *in vitro* assay

Art Unit: 1642

does not permit a single extrapolation of *in vitro* assays to human diagnostic efficacy with any reasonable degree of predictability. *In vitro* assays cannot easily assess cell-cell interactions that may be important in a particular pathological state.

Further, it is well known in the art that cultured cells, over a period time, lose phenotypic characteristics associated with their normal counterpart cell type. Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4) teach that it is recognized in the art that there are many differences between cultured cells and their counterparts *in vivo*. These differences stem from the dissociation of cells from a three-dimensional geometry and their propagation on a two-dimensional substrate. Specific cell interactions characteristic of histology of the tissue are lost. The culture environment lacks the input of the nervous and endocrine systems involved in homeostatic regulation *in vivo*. Without this control, cellular metabolism may be more constant *in vitro* but may not be truly representative of the tissue from which the cells were derived. This has often led to tissue culture being regarded in a rather skeptical light (p. 4, see Major Differences *In Vitro*). Further, Dermer (Bio/Technology, 1994, 12:320) teaches that, "petri dish cancer" is a poor representation of malignancy, with characteristics profoundly different from the human disease. Dermer teaches that when a normal or malignant body cell adapts to immortal life in culture, it takes an evolutionary type step that enables the new line to thrive in its artificial environment. This step transforms a cell from one that is stable and differentiated to one that is not. Yet normal or malignant cells *in vivo* are not like that. The reference states that evidence of the contradictions between life on the bottom of a lab dish and in the body

Art Unit: 1642

has been in the scientific literature for more than 30 years. Clearly it is well known in the art that cells in culture exhibit characteristics different from those *in vivo* and cannot duplicate the complex conditions of the *in vivo* environment involved in host-tumor and cell-cell interactions.

Further, Drexler et al (Leukemia and Lymphoma, 1993, 9:1-25) specifically teach, in the study of Hodgkin and Reed-Sternberg cancer cells in culture, that the acquisition or loss of certain properties during adaptation to culture systems cannot be excluded. Drexler et al teach that only a few cell lines containing cells that resemble the *in-vivo* cancer cells have been established and even for the bona fide cancer cell lines it is difficult to prove that the immortalized cells originated from a specific cancer cell (see abstract).

Gura (Science, 1997, 278:1041-1042) teaches that researchers face the problem of sifting through potential anticancer agents to find ones promising enough to make human clinical trials worthwhile and teach that since formal screening began in 1955, many thousands of drugs have shown activity in either cell or animal models but that only 39 have actually been shown to be useful for chemotherapy (p. 1041, see first and second para). Because of the known unpredictability of the art, in the absence of experimental evidence, no one skilled in the art would accept the assertion any antibody or HER2 antibody could be predictably used as an anti-cancer agent for cancer therapeutic strategies as inferred by the claim and as contemplated by the specification. Further, the refractory nature of cancer to drugs is well known in the art. Jain (Sci. Am., 1994, 271:58-65) teaches that tumors resist penetration by drugs (p.58, col 1) and that

Art Unit: 1642

scientists need to put expanded effort into uncovering the reasons why therapeutic agents that show encouraging promise in the laboratory often turn out to be ineffective in the treatment of common solid tumors (p. 65, col 3). Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39) teaches that solid tumors resist destruction by chemotherapy agents and that although strategies to overcome defense mechanisms of neoplastic cells have been developed and tested in a number of patients, success has been limited and further teaches that it is certainly possible that cancer cells possess many as yet undefined additional molecular mechanisms to defeat chemotherapy treatment strategies and if this is true, designing effective chemotherapeutic regimens for solid tumors may prove a daunting task (para bridging pages 29-30) and concludes that knowledge about the physical barriers to drug delivery in tumors is a work in progress (p. 36, col 2). It is clear that based on the state of the art, in the absence of experimental evidence, no one skilled in the art would accept the assertion that any antibody or HER2 antibody could be predictably used as an anti-cancer agent for cancer therapeutic strategies as inferred by the claim and as contemplated by the specification. In addition, anti-tumor agents must accomplish several tasks to be effective. They must be delivered into the circulation that supplies the tumor and interact at the proper site of action and must do so at a sufficient concentration and for a sufficient period of time. Also, the target cell must not have an alternate means of survival despite action at the proper site for the drug. In addition variables such as biological stability, half-life or clearance from the blood are important parameters in achieving successful therapy. The agent may be inactivated *in vivo* before producing a

Art Unit: 1642

sufficient effect, for example, by degradation, immunological activation or due to an inherently short half-life of the agent. In addition, the agent may not otherwise reach the target because of its inability to penetrate tissues or cells where its activity is to be exerted, may be absorbed by fluids, cells and tissues where the agent has no effect, circulation into the target area may be insufficient to carry the agent and a large enough local concentration may not be established. The specification provides insufficient guidance with regard to these issues and provides no working examples which would provide guidance to one skilled in the art and no evidence has been provided which would allow one of skill in the art to predict that the claimed invention would function as inferred and contemplated by the specification with a reasonable expectation of success. In view of the above, one of skill in the art would be forced into undue experimentation to practice the claimed invention.

Further, One cannot extrapolate the teaching of the specification to the scope of the claims because although the specification claims a method using any antibody to HER2 or mAb74, it is well known in the art that it is HERCEPTIN, and not any HER2 antibody, which is postulated as a novel and attractive therapeutic strategy in patients with cancer overexpressing HER2. It is clear that it is well known in the art that HERCEPTIN is an effective anti-cancer agent in tumors that overexpress HER2. The specification does not teach how to make a therapeutic antibody with the properties required for treatment of patients with cancer overexpressing HER2 so that it will function as claimed. For example, Stancovski, et al (PNAS, USA, 88:8691-8695, 1991) characterized the effects of various antibodies that bind the extracellular domain of



Art Unit: 1642

ErbB2 upon the growth of tumor cells. Stancovski, et al teach, while some anti-ErbB2 antibodies inhibit tumor growth, at least one of the anti-ErbB2 antibodies actually accelerates tumor growth (page 8693, column 1). This phenomenon was also reported in Lewis, et al (Cancer Immunology Immunotherapy 37: 255-263, 1993). US Patent No. 5,677,171 teaches that not every anti-ErbB2 antibody can be used as effectively as monoclonal antibody 4D5 (col 18, lines 15-23). More specifically, '171 teaches that some anti-ErbB-2 antibodies inhibited growth to a lesser extent than mAb 4D5 while others failed to inhibit growth. Further, Strobel, et al (Gynecologic Oncology 73: 362-367, 1999) teach discordant effects of contacting cancer cells with two different neutralizing monoclonal antibodies, i.e., antibodies that block the function of the receptor protein to which they specifically bind (abstract). Despite the fact that both anti-receptor antibodies had been shown to block ligand binding to the receptor, Strobel, et al found that only one of the antibodies could be used effectively to block cancer cell adhesion to inhibit malignancy. The specification provides insufficient guidance with regard to these issues and provides no working examples which would provide guidance to one skilled in the art and no evidence has been provided which would allow one of skill in the art to predict that the broadly claimed method will function as claimed with a reasonable expectation of success.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura B. Goddard, Ph.D. whose telephone number is (571) 272-8788. The examiner can normally be reached on 8:00am-5:00pm.

Art Unit: 1642


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Laura B Goddard, Ph.D.

Examiner

Art Unit 1642



SUSAN UNGAR, Ph.D.  
PRIMARY EXAMINER